OptiBiotix Health PLC
LSE:OPTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OptiBiotix Health PLC
Income from Continuing Operations
OptiBiotix Health PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OptiBiotix Health PLC
LSE:OPTI
|
Income from Continuing Operations
-£191k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
42%
|
CAGR 10-Years
17%
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£35.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Income from Continuing Operations
-$287.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£47.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Income from Continuing Operations
-£30.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-9%
|
|
|
Niox Group PLC
LSE:NIOX
|
Income from Continuing Operations
£7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
OptiBiotix Health PLC
Glance View
Optibiotix Health Plc is engaged in the research and development of compounds that modify the human microbiome. is a life sciences company. The firm is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. The Company’s technology platforms include OptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The Company’s OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. Its OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiome, SlimBiome Medical and WellBiome.
See Also
What is OptiBiotix Health PLC's Income from Continuing Operations?
Income from Continuing Operations
-191k
GBP
Based on the financial report for Jun 30, 2025, OptiBiotix Health PLC's Income from Continuing Operations amounts to -191k GBP.
What is OptiBiotix Health PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
17%
Over the last year, the Income from Continuing Operations growth was 94%.
